Company intelligence / Profile preview
Immodulon Therapeutics
London, United Kingdomimmodulon.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Immodulon's lead candidate IMM‑101 demonstrated a significant increase in median overall survival when combined with gemcitabine in metastatic pancreatic cancer patients during a randomized clinical trial—a reported improvement of up to 59% over gemcitabine alone. The company was preparing to advance into pivotal trials following positive Phase II data. Its approach leverages innate immune priming via dendritic cell activation and aims to complement standard-of-care therapies without increasing toxicity.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Vaccine (heat-killed whole cell)BiologicImmunomodulator
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Biodesix – collaboration on biomarker discovery using the Diagnostic Cortex machine learning platform for patient selection in pancreatic cancer trials with IMM–101.AIO–Studien–gGmbH – listed as sponsor/collaborator on some studies.
Beyond the preview
Go deeper on Immodulon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immodulon Therapeutics.